Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients

Koppert, Linetta B.; Janssen‐Heijnen, M.L.G.; Louwman, Marieke W. J.; Lemmens, Valery; Wijnhoven, Bas P. L.; Tilanus, Hugo W.; Coebergh, Jan Willem

doi:10.1097/01.meg.0000108331.52416.f1

Cited by 34 publications

(25 citation statements)

References 33 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they were unable to directly respond to the question regarding the incremental effect of epirubicin and took place in a context of a striking increase in toxicity [12][13][14]. These outcomes from randomized controlled trials (RCTs) failed to resolve doubts as to the applicability of 'intensified' therapies in the real-world conditions of clinical practice of our study in which patients are often elderly, with impaired performance status, and a high percentage of whom suffer chronic comorbidities [23]. The paucity of data from appropriately designed RCTs with a suitable sample size is the main reason why this issue continues to be relevant even today, projecting itself in our activity daily, debates, and research, which justifies conducting the analysis we present here [15].…”

Section: Discussionmentioning

confidence: 82%

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

Carmona-Bayonas¹,

Jiménez‐Fonseca

Custodio

et al. 2017

Gastric Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

Carmona-Bayonas¹,

Jiménez‐Fonseca

Custodio

et al. 2017

Gastric Cancer

View full text Add to dashboard Cite

show abstract

“…This is confirmed by the higher prevalence of those diseases among patients with smoking-related tumours: cancers of the stomach, lung, bladder, and kidney (Janssen-Heijnen et al , 1998; Koppert et al , 2004). Diabetes was more frequent among low SES for patients with cancers of the colorectum, pancreas, lung, breast, corpus uteri or prostate, or melanoma or NHL.…”

Section: Discussionmentioning

confidence: 82%

A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status

et al. 2010

View full text Add to dashboard Cite

Background:Comorbidity and socioeconomic status (SES) may be related among cancer patients.Method:Population-based cancer registry study among 72 153 patients diagnosed during 1997–2006.Results:Low SES patients had 50% higher risk of serious comorbidity than those with high SES. Prevalence was increased for each cancer site. Low SES cancer patients had significantly higher risk of also having cardiovascular disease, chronic obstructive pulmonary diseases, diabetes mellitus, cerebrovascular disease, tuberculosis, dementia, and gastrointestinal disease. One-year survival was significantly worse in lowest vs highest SES, partly explained by comorbidity.Conclusion:This illustrates the enormous heterogeneity of cancer patients and stresses the need for optimal treatment of cancer patients with a variety of concomitant chronic conditions.

show abstract

“…Another limitation is the lack of information on patients' co-morbidity status, which may vary between different oesophago-gastric cancers,[30] and deprivation groups. However, if more deprived patients had a greater co-morbidity burden, one could again expect this to have mainly influenced surgical treatment use (because of the greater anaesthetic risk of patients with higher co-morbidity burden).…”

Section: Discussionmentioning

confidence: 99%

Trends and variation in the management of oesophagogastric cancer patients: a population-based survey

Lyratzopoulos

Barbiere

Gajperia

et al. 2009

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundPrevious evidence indicates potential variation in the quality of care of cancer patients. We aimed to examine whether recent changes in the treatment of oesophagogastric cancers have been distributed equally among different patient subgroups.MethodsWe analysed population-based cancer registry data about the treatment patterning of oesophagogastric cancer (other than oesophageal squamous cell carcinoma) during 1995-2006.ResultsThere were 14,077 patients aged ≥40 years (69% men). There was only limited information on stage, and no information on co-morbidity status. During successive triennia, curative surgery use decreased from 28% to 20% (p < 0.001) whilst chemotherapy use increased from 9% to 30% (p < 0.001). Use of palliative surgery and of radiotherapy increased significantly but modestly (7% to 10%, and 9% to 11%, respectively). In multivariable logistic regression adjusting for age group, gender, diagnosis period and tumour type, curative surgery and chemotherapy were used less frequently in more deprived patients [per increasing deprivation group Odds Ratio (OR) = 0.96, 95% Confidence Interval (CI) 0.93-0.99, and OR = 0.90, 95%CI 0.87-0.93, respectively, p < 0.001 for both)]. Chemotherapy was also used less frequently in women (OR = 0.76, p < 0.001).ConclusionsDuring the study period, curative surgery decreased by a third and chemotherapy use increased by more than three-fold, reflecting improvements in the appropriateness and quality of management, but chemotherapy use, in particular, was unequal, both by socioeconomic status and gender.

show abstract

Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients

Abstract: In terms of comorbidity at diagnosis, cardia adenocarcinoma patients resemble distal oesophageal adenocarcinoma patients rather than gastric subcardia carcinoma patients, with likewise equal age and gender distribution.

Cited by 34 publications

References 33 publications

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status

Trends and variation in the management of oesophagogastric cancer patients: a population-based survey

Contact Info

Product

Resources

About